Samsung is intensifying its focus on digital health, with its latest move being a significant investment in Element Biosciences, a US-based genomics technology company. This $175 million investment makes Samsung the largest shareholder in the company, which specializes in next-generation DNA sequencing and multiomics platforms for biomedical and clinical research. This strategic decision aligns with Samsung’s ambition to broaden its reach in digital health and precision medicine technologies. TM Roh, co-CEO of Samsung Electronics, emphasized that the collaboration, coupled with Samsung’s expertise in AI, will foster synergies that shape the future of personalized medicine. Samsung’s health initiatives are increasingly geared towards predictive and preventative wellness, leveraging AI to analyze data from wearables and other devices to offer personalized wellness guidance.
How is Samsung expanding its health footprint with a major investment in a US biosciences company?
